Linkers in fragment-based drug design: an overview of the literature

References

• Walsh L, Erlanson DA, de Esch IJP, et al. Fragment-to-lead medicinal chemistry publications in 2021. J Med Chem. 2023;66:1137–1156. doi: 10.1021/acs.jmedchem.2c01827
   PubMedGoogle Scholar
• de Esch IJP, Erlanson DA, Jahnke W, et al. Fragment-to-lead medicinal chemistry publications in 2020. J Med Chem. 2022;65:84–99. doi: 10.1021/acs.jmedchem.1c01803
   PubMed Web of Science ®Google Scholar
• Shuker SB, Hajduk PJ, Meadows RP, et al. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996;274(5292):1531–1534. doi: 10.1126/science.274.5292.1531
   PubMed Web of Science ®Google Scholar
• Rees DC, Hirsch AKH, Erlanson DA. Introduction to the themed collection on fragment-based drug discovery. RSC Med Chem. 2022;13:1439–1439. doi: 10.1039/D2MD90037H
   PubMedGoogle Scholar
• Kirsch P, Hartman AM, Hirsch AKH, et al. Concepts and core principles of fragment-based drug design. Molecules. 2019;24:4309. doi: 10.3390/molecules24234309
   PubMed Web of Science ®Google Scholar
• Bancet A, Raingeval C, Lomberget T, et al. Fragment linking strategies for structure-based drug design. J Med Chem. 2020;63:11420–11435. doi: 10.1021/acs.jmedchem.0c00242
   PubMed Web of Science ®Google Scholar
• Bedwell EV, McCarthy WJ, Coyne AG, et al. Development of potent inhibitors by fragment-linking strategies. Chem Biol Drug Des. 2022;100(4):469–486. doi: 10.1111/cbdd.14120
   PubMed Web of Science ®Google Scholar
• Ichihara O, Barker J, Law RJ, et al. Compound design by fragment-linking. Mol Inform. 2011;30:298–306. doi: 10.1002/minf.201000174
   PubMed Web of Science ®Google Scholar
• Jencks WP. On the attribution and additivity of binding energies. Proc Natl Acad Sci. 1981;78:4046–4050. doi: 10.1073/pnas.78.7.4046
   PubMed Web of Science ®Google Scholar
• Hajduk PJ, Sheppard G, Nettesheim DG, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc. 1997;119:5818–5827. doi: 10.1021/ja9702778
   Web of Science ®Google Scholar
• Jordan JB, Whittington DA, Bartberger MD, et al. Fragment-linking approach using 19F NMR spectroscopy to obtain highly potent and selective inhibitors of β-secretase. J Med Chem. 2016;59(8):3732–3749. doi: 10.1021/acs.jmedchem.5b01917
   PubMed Web of Science ®Google Scholar
• Howard N, Abell C, Blakemore W, et al. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J Med Chem. 2006;49:1346–1355. doi: 10.1021/jm050850v
   PubMed Web of Science ®Google Scholar
• Matsui Y, Yasumatsu I, Asahi T, et al. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator. Bioorg Med Chem. 2017;25:3540–3546. doi: 10.1016/j.bmc.2017.05.004
   PubMed Web of Science ®Google Scholar
• Drapier T, Geubelle P, Bouckaert C, et al. Enhancing action of positive allosteric modulators through the design of dimeric compounds. J Med Chem. 2018;61:5279–5291. doi: 10.1021/acs.jmedchem.8b00250
   PubMed Web of Science ®Google Scholar
• Möbitz H, Machauer R, Holzer P, et al. discovery of potent, selective, and structurally novel Dot1L inhibitors by a fragment linking approach. ACS Med Chem Lett. 2017;8(3):338–343. doi: 10.1021/acsmedchemlett.6b00519
   PubMed Web of Science ®Google Scholar
• Iannelli G, Milite C, Marechal N, et al. Turning nonselective inhibitors of type I protein arginine methyltransferases into potent and selective inhibitors of protein arginine methyltransferase 4 through a deconstruction–reconstruction and fragment-growing approach. J Med Chem. 2022;65:11574–11606. doi: 10.1021/acs.jmedchem.2c00252
   PubMedGoogle Scholar
• Barker JJ, Barker O, Courtney SM, et al. Discovery of a novel Hsp90 inhibitor by fragment linking. ChemMedchem. 2010;5:1697–1700. doi: 10.1002/cmdc.201000219
   PubMed Web of Science ®Google Scholar
• Pang Y-P, Quiram P, Jelacic T, et al. Highly potent, selective, and low cost Bis-tetrahydroaminacrine inhibitors of acetylcholinesterase: STEPS TOWARD NOVEL DRUGS for TREATING ALZHEIMER’S DISEASE. J Biol Chem. 1996;271:23646–23649. doi: 10.1074/jbc.271.39.23646
   PubMed Web of Science ®Google Scholar
• Szczepankiewicz BG, Liu G, Hajduk PJ, et al. Discovery of a potent, selective protein tyrosine phosphatase 1b inhibitor using a linked-fragment strategy. J Am Chem Soc. 2003;125:4087–4096. doi: 10.1021/ja0296733
   PubMed Web of Science ®Google Scholar
• Liu G, Xin Z, Liang H, et al. Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem. 2003;46:3437–3440. doi: 10.1021/jm034088d
   PubMed Web of Science ®Google Scholar
• Petros AM, Huth JR, Oost T, et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett. 2010;20:6587–6591. doi: 10.1016/j.bmcl.2010.09.033
   PubMed Web of Science ®Google Scholar
• El Bakali J, Blaszczyk M, Evans JC, et al. Chemical validation of mycobacterium tuberculosis phosphopantetheine adenylyltransferase using fragment linking and CRISPR interference. Angew Chem. 2023;135:e202300221. doi: 10.1002/ange.202300221
   Google Scholar
• Mousnier A, Bell AS, Swieboda DP, et al. Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nat Chem. 2018:10;599–606. doi: 10.1038/s41557-018-0039-2. .
   PubMed Web of Science ®Google Scholar
• Frank AO, Feldkamp MD, Kennedy JP, et al. Discovery of a potent inhibitor of replication protein a protein–protein interactions using a fragment-linking approach. J Med Chem. 2013;56:9242–9250. doi: 10.1021/jm401333u
   PubMed Web of Science ®Google Scholar
• Gelin M, Paoletti J, Nahori M-A, et al. From substrate to fragments to inhibitor active in vivo against Staphylococcus aureus. ACS Infect Dis. 2020;6:422–435. doi: 10.1021/acsinfecdis.9b00368
   PubMed Web of Science ®Google Scholar
• Tao Z-F, Hasvold L, Wang L, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett. 2014;5:1088–1093. doi: 10.1021/ml5001867
   PubMed Web of Science ®Google Scholar
• Fang W-S, Sun D, Yang S, et al. Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR. Bioorg Chem. 2019;92:103253. doi: 10.1016/j.bioorg.2019.103253
   PubMed Web of Science ®Google Scholar
• Solbak SMØ, Zang J, Narayanan D, et al. Developing inhibitors of the p47phox–p22phox Protein–protein interaction by fragment-based drug discovery. J Med Chem. 2020;63:1156–1177. doi: 10.1021/acs.jmedchem.9b01492
   PubMedGoogle Scholar
• Burgess LE, Newhouse BJ, Ibrahim P, et al. Potent selective nonpeptidic inhibitors of human lung tryptase. Proc Natl Acad Sci. 1999;96(15):8348–8352. doi: 10.1073/pnas.96.15.8348
   PubMed Web of Science ®Google Scholar
• Sledz P, Silvestre HL, Hung AW, et al. Optimization of the Interligand overhauser effect for fragment linking: application to inhibitor discovery against mycobacterium tuberculosis pantothenate synthetase. J Am Chem Soc. 2010;132:4544–4545. doi: 10.1021/ja100595u
   PubMed Web of Science ®Google Scholar
• Becattini B, Culmsee C, Leone M, et al. Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci. 2006;103:12602–12606. doi: 10.1073/pnas.0603460103
   PubMed Web of Science ®Google Scholar
• Ward RA, Brassington C, Breeze AL, et al. Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation. J Med Chem. 2012;55:3285–3306. doi: 10.1021/jm201734r
   PubMed Web of Science ®Google Scholar
• Brear P, De Fusco C, Georgiou KH, et al. Specific inhibition of CK2α from an anchor outside the active site. Chem Sci. 2016;7:6839–6845. doi: 10.1039/C6SC02335E
   PubMed Web of Science ®Google Scholar
• Wang P-F, Wang Z-F, Qiu H-Y, et al. Identification and biological evaluation of novel type II B-RafV600E inhibitors. ChemMedchem. 2018;13:2558–2566. doi: 10.1002/cmdc.201800574
   PubMed Web of Science ®Google Scholar
• Grädler U, Schwarz D, Blaesse M, et al. Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies. Bioorg Med Chem Lett. 2019;29:126717. doi: 10.1016/j.bmcl.2019.126717
   PubMed Web of Science ®Google Scholar
• Floresta G, Fallica AN, Patamia V, et al. From far West to East: joining the molecular architecture of imidazole-like ligands in HO-1 complexes. Pharmaceuticals. 2021;14:1289. doi: 10.3390/ph14121289
   Web of Science ®Google Scholar
• Wu X, Ramesh R, Wang J, et al. Small molecules targeting the rna-binding protein HuR Inhibit Tumor Growth in Xenografts. J Med Chem. 2023;66:2032–2053. doi: 10.1021/acs.jmedchem.2c01723
   PubMedGoogle Scholar
• Trapero A, Pacitto A, Singh V, et al. fragment-based approach to targeting Inosine-5′-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis. J Med Chem. 2018;61:2806–2822. doi: 10.1021/acs.jmedchem.7b01622
   PubMed Web of Science ®Google Scholar
• Swayze EE, Jefferson EA, Sannes-Lowery KA, et al. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J Med Chem. 2002;45:3816–3819. doi: 10.1021/jm0255466
   PubMed Web of Science ®Google Scholar
• Huth JR, Park C, Petros AM, et al. discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des. 2007;70:1–12. doi: 10.1111/j.1747-0285.2007.00535.x
   PubMed Web of Science ®Google Scholar
• Hung AW, Silvestre HL, Wen S, et al. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew Chem Int Ed. 2009;48:8452–8456. doi: 10.1002/anie.200903821
   PubMed Web of Science ®Google Scholar
• Rega MF, Wu B, Wei J, et al. SAR by Interligand Nuclear Overhauser Effects (ILOEs) Based discovery of acylsulfonamide compounds active against Bcl-Xl and Mcl-1. J Med Chem. 2011;54:6000–6013. doi: 10.1021/jm200826s
   PubMed Web of Science ®Google Scholar
• Kohlmann A, Zech SG, Li F, et al. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J Med Chem. 2013;56:1023–1040. doi: 10.1021/jm3014844
   PubMed Web of Science ®Google Scholar
• Villemagne B, Flipo M, Blondiaux N, et al. Ligand efficiency driven design of new inhibitors of mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. J Med Chem. 2014;57:4876–4888. doi: 10.1021/jm500422b
   PubMed Web of Science ®Google Scholar
• Surade S, Ty N, Hengrung N, et al. A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Biochem J. 2014;458:387–394. doi: 10.1042/BJ20131127
   PubMed Web of Science ®Google Scholar
• Ahmed-Belkacem A, Colliandre L, Ahnou N, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016;7(1):12777. doi: 10.1038/ncomms12777
   PubMedGoogle Scholar
• Benmansour F, Trist I, Coutard B, et al. Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design. Eur J Med Chem. 2017;125:865–880. doi: 10.1016/j.ejmech.2016.10.007
   PubMed Web of Science ®Google Scholar
• Zeller MJ, Favorov O, Li K, et al. SHAPE-enabled fragment-based ligand discovery for RNA. Proc Natl Acad Sci. 2022;119:e2122660119. doi: 10.1073/pnas.2122660119
   PubMed Web of Science ®Google Scholar
• Bosc D, Camberlein V, Gealageas R, et al. Kinetic target-guided synthesis: reaching the age of maturity: miniperspective. J Med Chem. 2020;63(8):3817–3833. doi: 10.1021/acs.jmedchem.9b01183
   PubMed Web of Science ®Google Scholar
• Frei P, Hevey R, Ernst B. Dynamic combinatorial chemistry: a new methodology comes of age. Chem – Eur J. 2019;25(1):60–73. doi: 10.1002/chem.201803365.
   PubMed Web of Science ®Google Scholar
• Mondal M, Hirsch AKH. Dynamic combinatorial chemistry: a tool to facilitate the identification of inhibitors for protein targets. Chem Soc Rev. 2015;44:2455–2488. doi: 10.1039/C4CS00493K
   PubMed Web of Science ®Google Scholar
• Nguyen R, Huc I. Using an enzyme’s active site to template inhibitors. Angew Chem Int Ed. 2001;40:1774–1776. doi: 10.1002/1521-3773(20010504)40:9<1774:AID-ANIE17740>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Oueis E, Sabot C, Renard P-Y. New insights into the kinetic target-guided synthesis of protein ligands. Chem Commun. 2015;51:12158–12169. doi: 10.1039/C5CC04183J
   PubMed Web of Science ®Google Scholar
• Congreve MS, Davis DJ, Devine L, et al. Detection of ligands from a dynamic combinatorial library by X-ray crystallography. Angew Chem Int Ed. 2003;42(37):4479–4482. doi: 10.1002/anie.200351951
   PubMed Web of Science ®Google Scholar
• Gelin M, Poncet-Montange G, Assairi L, et al. Screening and in situ synthesis using crystals of a NAD kinase lead to a potent antistaphylococcal compound. Structure. 2012;20:1107–1117. doi: 10.1016/j.str.2012.03.024
   PubMed Web of Science ®Google Scholar
• Huc I, Lehn J-M. Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. Proc Natl Acad Sci. 1997;94(6):2106–2110. doi: 10.1073/pnas.94.6.2106.
   PubMed Web of Science ®Google Scholar
• Hochgürtel M, Biesinger R, Kroth H, et al. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. J Med Chem. 2003;46:356–358. doi: 10.1021/jm025589m
   PubMed Web of Science ®Google Scholar
• Mondal M, Radeva N, Köster H, et al. Structure-based design of inhibitors of the aspartic protease endothiapepsin by exploiting dynamic combinatorial chemistry. Angew Chem Int Ed. 2014;53:3259–3263. doi: 10.1002/anie.201309682
   PubMed Web of Science ®Google Scholar
• Clipson AJ, Bhat VT, McNae I, et al. Bivalent enzyme inhibitors discovered using dynamic covalent chemistry. Chem – Eur J. 2012;18(34):10562–10570. doi: 10.1002/chem.201201507
   PubMed Web of Science ®Google Scholar
• Lewis WG, Green LG, Grynszpan F, et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed. 2002;41:1053–1057. doi: 10.1002/1521-3773(20020315)41:6<1053:AID-ANIE1053>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed. 2001;40:2004–2021. doi: 10.1002/1521-3773(20010601)40:11<2004:AID-ANIE2004>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Mondal M, Unver MY, Pal A, et al. Fragment-Based drug design facilitated by protein-templated click chemistry: fragment linking and optimization of inhibitors of the aspartic protease endothiapepsin. Chem – Eur J. 2016;22(42):14826–14830. doi: 10.1002/chem.201603001
   PubMed Web of Science ®Google Scholar
• Pomeislová A, Vrzal L, Kozák J, et al. Kinetic target-guided synthesis of small-molecule G-quadruplex stabilizers. ChemistryOpen. 2020;9:1236–1250. doi: 10.1002/open.202000261
   PubMed Web of Science ®Google Scholar
• Molęda Z, Zawadzka A, Czarnocki Z, et al. “Clicking“fragment leads to novel dual-binding cholinesterase inhibitors. Bioorg Med Chem. 2021;42:116269. doi: 10.1016/j.bmc.2021.116269
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ota Y, Kasuya Y, et al. An unexpected example of protein-templated click chemistry. Angew Chem Int Ed. 2010;49:6817–6820. doi: 10.1002/anie.201002205
   PubMed Web of Science ®Google Scholar
• Mocharla VP, Colasson B, Lee LV, et al. In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. Angew Chem. 2005;117:118–122. doi: 10.1002/ange.200461580
   Google Scholar
• Whiting M, Muldoon J, Lin Y-C, et al. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed. 2006;45:1435–1439. doi: 10.1002/anie.200502161
   PubMed Web of Science ®Google Scholar
• Grimster NP, Stump B, Fotsing JR, et al. Generation of candidate ligands for nicotinic acetylcholine receptors via in situ click chemistry with a soluble acetylcholine binding protein template. J Am Chem Soc. 2012;134:6732–6740. doi: 10.1021/ja3001858
   PubMed Web of Science ®Google Scholar
• Peruzzotti C, Borrelli S, Ventura M, et al. Probing the binding site of Abl Tyrosine kinase using in situ click chemistry. ACS Med Chem Lett. 2013;4:274–277. doi: 10.1021/ml300394w
   PubMed Web of Science ®Google Scholar
• Lisurek M, Rupp B, Wichard J, et al. Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept. Mol Divers. 2010;14:401–408. doi: 10.1007/s11030-009-9187-z
   PubMed Web of Science ®Google Scholar
• Jaegle M, Steinmetzer T, Rademann J. Protein-templated formation of an inhibitor of the blood coagulation factor xa through a background-free amidation reaction. Angew Chem Int Ed. 2017;56:3718–3722. doi: 10.1002/anie.201611547
   PubMed Web of Science ®Google Scholar
• Kwarcinski FE, Steffey ME, Fox CC, et al. Discovery of bivalent kinase inhibitors via enzyme-templated fragment elaboration. ACS Med Chem Lett. 2015;6:898–901. doi: 10.1021/acsmedchemlett.5b00167
   PubMed Web of Science ®Google Scholar
• Lossouarn A, Puteaux C, Bailly L, et al. Metalloenzyme-mediated thiol-yne addition towards photoisomerizable fluorescent dyes. Chem – Eur J. 2022;28:e202202180. doi: 10.1002/chem.202202180
   PubMed Web of Science ®Google Scholar
• Nacheva K, Kulkarni SS, Kassu M, et al. Going beyond binary: rapid identification of protein–protein interaction modulators using a multifragment kinetic target-guided synthesis approach. J Med Chem. 2023;66(7):5196–5207. doi: 10.1021/acs.jmedchem.3c00108
   PubMed Web of Science ®Google Scholar
• Kulkarni SS, Hu X, Doi K, et al. Screening of protein–protein interaction modulators via sulfo-click kinetic target-guided synthesis. ACS Chem Biol. 2011;6:724–732. doi: 10.1021/cb200085q
   PubMed Web of Science ®Google Scholar
• Mancini F, Unver MY, Elgaher WAM, et al. Protein-templated hit identification through an ugi four-component reaction. Chem – Eur J. 2020;26(64):14585–14593. doi: 10.1002/chem.202002250
   PubMed Web of Science ®Google Scholar
• Gladysz R, Vrijdag J, Van Rompaey D, et al. Efforts towards an on-target version of the Groebke–Blackburn–Bienaymé (GBB) reaction for discovery of druglike urokinase (uPA) inhibitors. Chem – Eur J. 2019;25:12380–12393. doi: 10.1002/chem.201901917
   PubMed Web of Science ®Google Scholar
• Fjellström O, Akkaya S, Beisel H-G, et al. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. PLoS One. 2015;10(1):e0113705. doi: 10.1371/journal.pone.0113705
   PubMed Web of Science ®Google Scholar
• Yu W, Xiao H, Lin J, et al. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013;56:4402–4412. doi: 10.1021/jm400080c
   PubMed Web of Science ®Google Scholar
• Scheufler C, Möbitz H, Gaul C, et al. Optimization of a fragment-based screening hit toward potent DOT1L inhibitors interacting in an induced binding pocket. ACS Med Chem Lett. 2016;7:730–734. doi: 10.1021/acsmedchemlett.6b00168
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). | MOEsaic | PSILO. [cited 2023 May 3]. Available from: https://www.chemcomp.com/Products.htm.
   Google Scholar
• Böhm H-J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 1992;6:61–78. doi: 10.1007/BF00124387
   PubMed Web of Science ®Google Scholar
• Dey F, Caflisch A. Fragment-based de novo ligand design by multiobjective evolutionary optimization. J Chem Inf Model. 2008;48:679–690. doi: 10.1021/ci700424b
   PubMed Web of Science ®Google Scholar
• Wang R, Gao Y, Lai L. LigBuilder: a multi-purpose program for structure-based drug design. Mol Model Annu. 2000;6:498–516. doi: 10.1007/s0089400060498
   Web of Science ®Google Scholar
• Yuan Y, Pei J, Lai L. LigBuilder 2: a practical de novo drug design approach. J Chem Inf Model. 2011;51:1083–1091. doi: 10.1021/ci100350u
   PubMed Web of Science ®Google Scholar
• Yuan Y, Pei J, Lai L. LigBuilder V3: a multi-target de novo drug design approach. Front Chem. 2020 [cited 2023 Apr 27];8. doi: 10.3389/fchem.2020.00142
   Web of Science ®Google Scholar
• Pascoini AL, Federico LB, Arêas ALF, et al. In silico development of new acetylcholinesterase inhibitors. J Biomol Struct Dyn. 2019;37:1007–1021. Cited: in: PMID: 29607738. doi: 10.1080/07391102.2018.1447513
   PubMed Web of Science ®Google Scholar
• de Souza Neto LR, Moreira-Filho JT, Neves BJ, et al. In silico strategies to support fragment-to-lead optimization in drug discovery. Front Chem. 2020 [cited 2023 Apr 28];8. doi: 10.3389/fchem.2020.00093.
   PubMed Web of Science ®Google Scholar
• Segler MHS, Kogej T, Tyrchan C, et al. Generating focused molecule libraries for drug discovery with recurrent neural networks. ACS Cent Sci. 2018;4:120–131. doi: 10.1021/acscentsci.7b00512
   PubMed Web of Science ®Google Scholar
• Yang Y, Zheng S, Su S, et al. SyntaLinker: automatic fragment linking with deep conditional transformer neural networks. Chem Sci. 2020;11:8312–8322. doi: 10.1039/D0SC03126G
   PubMed Web of Science ®Google Scholar
• Imrie F, Bradley AR, van der Schaar M, et al. Deep generative models for 3D linker design. J Chem Inf Model. 2020;60:1983–1995. doi: 10.1021/acs.jcim.9b01120
   PubMed Web of Science ®Google Scholar
• Gómez-Bombarelli R, Wei JN, Duvenaud D, et al. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent Sci. 2018;4:268–276. doi: 10.1021/acscentsci.7b00572
   PubMed Web of Science ®Google Scholar
• Tan Y, Dai L, Huang W, et al. Drlinker: deep reinforcement learning for optimization in fragment linking design. J Chem Inf Model. 2022;62:5907–5917. doi: 10.1021/acs.jcim.2c00982
   PubMed Web of Science ®Google Scholar
• Bon M, Bilsland A, Bower J, et al. Fragment-based drug discovery—the importance of high-quality molecule libraries. Mol Oncol. 2022;16:3761–3777. doi: 10.1002/1878-0261.13277
   PubMed Web of Science ®Google Scholar
• Molinspiration Cheminformatics. [cited 2023 May 3]. Available from: https://www.molinspiration.com/.
   Google Scholar
• Sadybekov AA, Sadybekov AV, Liu Y, et al. Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. Nature. 2022;601:452–459. doi: 10.1038/s41586-021-04220-9
   PubMed Web of Science ®Google Scholar
• Lyu J, Wang S, Balius TE, et al. Ultra-large library docking for discovering new chemotypes. Nature. 2019;566:224–229. doi: 10.1038/s41586-019-0917-9
   PubMed Web of Science ®Google Scholar
• Bian Y, Feng Z, Yang P, et al. Integrated in silico fragment-based drug design: case study with allosteric modulators on metabotropic glutamate receptor 5. Aaps J. 2017;19:1235–1248. doi: 10.1208/s12248-017-0093-5
   PubMed Web of Science ®Google Scholar
• Degen J, Wegscheid-Gerlach C, Zaliani A, et al. On the art of compiling and using “drug-like” chemical fragment spaces. ChemMedchem. 2008;3:1503–1507. doi: 10.1002/cmdc.200800178
   PubMed Web of Science ®Google Scholar
• Boda K, Seidel T, Gasteiger J. Structure and reaction based evaluation of synthetic accessibility. J Comput Aided Mol Des. 2007;21:311–325. doi: 10.1007/s10822-006-9099-2
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi: 10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Schyman P, Liu R, Desai V, et al. vNN web server for ADMET predictions. Front Pharmacol. 2017 [cited 2023 May 3];8. doi: 10.3389/fphar.2017.00889
   PubMed Web of Science ®Google Scholar